The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis

• Published in: Current rheumatology reports Vol. 16; no. 12; p. 467
• Main Authors: Hoeltzel, Mark F., Oberle, Edward J., Robinson, Angela Byun, Agarwal, Arunima, Rider, Lisa G.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01-12-2014
• Subjects: Anti-Inflammatory Agents - therapeutic use; Calcinosis - diagnosis; Calcinosis - drug therapy; Calcinosis - etiology; Dermatomyositis - complications; Humans; Medicine; Medicine & Public Health; Pediatric Rheumatology (S Ozen; Rheumatology; Section Editor; Topical Collection on Pediatric Rheumatology; Juvenile dermatomyositis; Dystrophic calcification; Treatment; Calcinosis; Pathogenesis
• ISSN: 1523-3774; 1534-6307
• DOI: 10.1007/s11926-014-0467-y

Calcinosis is one of the hallmark sequelae of juvenile dermatomyositis (JDM), and despite recent progress in the therapy of JDM, dystrophic calcification still occurs in approximately one third of patients. This review discusses our current, albeit limited, understanding of risk factors for the development of calcinosis in JDM, as well as approaches to assessment, and current views on its pathogenesis. Anecdotal approaches to treating calcinosis associated with JDM, including both anti-inflammatory therapies and agents aimed at inhibiting the deposition of calcium hydroxyapatite, are reviewed. An improved understanding of the pathogenesis of calcinosis, the establishment of standardized measurement tools to assess calcinosis, and randomized controlled trials employing more sensitive outcome measures are needed to develop efficacious therapies for this often disabling complication.